CN1551782A - 嵌合黄病毒载体 - Google Patents

嵌合黄病毒载体 Download PDF

Info

Publication number
CN1551782A
CN1551782A CNA028149602A CN02814960A CN1551782A CN 1551782 A CN1551782 A CN 1551782A CN A028149602 A CNA028149602 A CN A028149602A CN 02814960 A CN02814960 A CN 02814960A CN 1551782 A CN1551782 A CN 1551782A
Authority
CN
China
Prior art keywords
virus
banzi
carrier
encephalitis
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028149602A
Other languages
English (en)
Chinese (zh)
Inventor
H
H·克利恩托斯
L·奥罗斯
C·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Biologics LLC
Original Assignee
Acambis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Inc filed Critical Acambis Inc
Publication of CN1551782A publication Critical patent/CN1551782A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA028149602A 2001-06-01 2002-05-31 嵌合黄病毒载体 Pending CN1551782A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29526501P 2001-06-01 2001-06-01
US60/295,265 2001-06-01

Publications (1)

Publication Number Publication Date
CN1551782A true CN1551782A (zh) 2004-12-01

Family

ID=23136958

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028149602A Pending CN1551782A (zh) 2001-06-01 2002-05-31 嵌合黄病毒载体

Country Status (11)

Country Link
US (2) US7569383B2 (https=)
EP (1) EP1401859B1 (https=)
JP (1) JP2005501532A (https=)
KR (1) KR100921592B1 (https=)
CN (1) CN1551782A (https=)
AU (1) AU2002322026B2 (https=)
BR (1) BR0210907A (https=)
CA (1) CA2448971C (https=)
ES (1) ES2439724T3 (https=)
PL (1) PL371187A1 (https=)
WO (1) WO2002102828A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103352029A (zh) * 2013-07-29 2013-10-16 中国人民解放军军事医学科学院微生物流行病研究所 一种乙脑/森林脑炎嵌合病毒及其应用
CN106574271A (zh) * 2014-06-20 2017-04-19 美国政府(由卫生和人类服务部的部长所代表) 嵌合西尼罗/登革病毒和使用方法
CN108040484A (zh) * 2014-12-11 2018-05-15 巴斯德研究院 基于慢病毒载体的日本脑炎免疫原性组合物
CN111798712A (zh) * 2020-07-15 2020-10-20 周晓庆 噬菌体侵染细菌3d智能模拟方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
CN1551782A (zh) * 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
KR101074175B1 (ko) 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
WO2004045529A2 (en) * 2002-11-15 2004-06-03 Acambis, Inc. West nile virus vaccine
AU2007297801A1 (en) * 2006-07-14 2008-03-27 Sanofi Pasteur Biologics Co. Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
EP2069483A4 (en) * 2006-09-29 2010-10-27 Sanofi Pasteur Biologics Co RECOMBINANT RHINOVIRAL VECTORS
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
MX2009004862A (es) 2006-11-07 2009-07-17 Sanofi Pasteur Biologics Co Estabilizacion de vacunas por liofilizacion.
EP2117589A4 (en) * 2007-01-31 2010-07-21 Sanofi Pasteur Biologics Co FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS
WO2009030872A1 (en) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Materials and methods for the treatment of hepatitis c
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
JP5779352B2 (ja) * 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
EP2257308A4 (en) * 2008-03-27 2012-06-27 Sanofi Pasteur Biologics Co RECOMBINANT RHINOVIRUS VECTORS
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US20120128713A1 (en) * 2009-03-16 2012-05-24 Sanofi Pasteur Limited Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
SG11201401733VA (en) * 2011-10-25 2014-09-26 Florida Gulf Coast University Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
SG10201912291YA (en) 2012-07-24 2020-02-27 Sanofi Pasteur Vaccine compositions
AU2013295016A1 (en) * 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
BE1024160B9 (fr) 2015-12-22 2017-12-06 Glaxosmithkline Biologicals Sa Formulation immunogène
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
KR20260047644A (ko) 2017-03-30 2026-04-08 더 유니버서티 어브 퀸슬랜드 키메라 분자 및 그의 용도
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University "immunoregulatory molecules and uses therefor"
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
AU2020273263A1 (en) * 2019-04-10 2021-12-02 Katholieke Universiteit Leuven Chimeric Zika-Japanese encephalitis virus

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
EP1018556B1 (en) 1991-09-19 2005-11-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Chimeric and/or growth-restricted flaviviruses
US6136561A (en) * 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
EP0977587B1 (en) 1997-02-28 2005-06-15 Acambis Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
KR20020030793A (ko) * 1999-08-20 2002-04-25 리차드 에이취 리저 β-글루쿠로니다제를 억제시키는 데에 사용되는아스파르트산 및 말산의 용도
AU1813901A (en) 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
CN1551782A (zh) * 2001-06-01 2004-12-01 ��������ķ������ 嵌合黄病毒载体
US6682883B1 (en) * 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
KR101131579B1 (ko) 2001-10-19 2012-03-30 사노피 파스테르 바이오로직스 씨오 동물의 플라비바이러스 감염 예방 및 치료 방법
KR101074175B1 (ko) 2002-01-15 2011-10-14 사노피 파스테르 바이오로직스 씨오 플라비바이러스 백신
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
WO2004045529A2 (en) 2002-11-15 2004-06-03 Acambis, Inc. West nile virus vaccine
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
WO2005040390A1 (en) 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. A recombinant vaccine using yellow fever virus as vector
WO2005049815A1 (en) 2003-11-21 2005-06-02 K.U.Leuven Research & Development Flavivirus replication
SG156666A1 (en) 2004-10-20 2009-11-26 Acambis Inc Vaccines against japanese encephalitis virus and west nile virus
CA2605924A1 (en) 2005-04-24 2006-11-02 Acambis Inc. Recombinant flavivirus vaccines
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103352029A (zh) * 2013-07-29 2013-10-16 中国人民解放军军事医学科学院微生物流行病研究所 一种乙脑/森林脑炎嵌合病毒及其应用
CN106574271A (zh) * 2014-06-20 2017-04-19 美国政府(由卫生和人类服务部的部长所代表) 嵌合西尼罗/登革病毒和使用方法
US10428313B2 (en) 2014-06-20 2019-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric West Nile/Dengue viruses and methods of use
CN106574271B (zh) * 2014-06-20 2020-06-16 美国政府(由卫生和人类服务部的部长所代表) 嵌合西尼罗/登革病毒和使用方法
CN108040484A (zh) * 2014-12-11 2018-05-15 巴斯德研究院 基于慢病毒载体的日本脑炎免疫原性组合物
CN108040484B (zh) * 2014-12-11 2022-04-26 巴斯德研究院 基于慢病毒载体的日本脑炎免疫原性组合物
CN111798712A (zh) * 2020-07-15 2020-10-20 周晓庆 噬菌体侵染细菌3d智能模拟方法
CN111798712B (zh) * 2020-07-15 2021-10-29 周晓庆 噬菌体侵染细菌3d智能模拟方法

Also Published As

Publication number Publication date
US20030044773A1 (en) 2003-03-06
WO2002102828A2 (en) 2002-12-27
EP1401859A2 (en) 2004-03-31
BR0210907A (pt) 2004-12-21
CA2448971A1 (en) 2002-12-27
ES2439724T3 (es) 2014-01-24
WO2002102828A3 (en) 2003-10-09
EP1401859B1 (en) 2013-08-07
US7569383B2 (en) 2009-08-04
EP1401859A4 (en) 2004-12-29
AU2002322026B2 (en) 2008-03-13
KR100921592B1 (ko) 2009-10-14
PL371187A1 (en) 2005-06-13
KR20040003043A (ko) 2004-01-07
US20110014229A1 (en) 2011-01-20
CA2448971C (en) 2013-11-26
JP2005501532A (ja) 2005-01-20

Similar Documents

Publication Publication Date Title
CN1551782A (zh) 嵌合黄病毒载体
CN1187088C (zh) 嵌合黄病毒疫苗
CN1298738C (zh) 修饰的麻疹病毒v蛋白
CN1602316A (zh) 黄病毒ns1亚单位疫苗
CN101048502A (zh) 具有自主复制能力的经修饰的人丙型肝炎病毒基因组rna
CN1829799A (zh) 含polii启动子和核酶的重组流感载体
CN1653183A (zh) 表达插入痘病毒基因组中的同源基因的重组痘病毒
CN1833022A (zh) 包含HCV的多蛋白NS3/NS4和多肽NS5b的组合物,包括相应核酸序列的表达载体及它们的治疗应用
CN1492923A (zh) 减毒的活疫苗
CN1460111A (zh) 来自gagp17和p24保守区域的HIV肽以及它们在例如疫苗中的应用
CN1688702A (zh) 表达rna病毒抗原表位的重组麻疹病毒在制备疫苗组合物中的用途
CN1616670A (zh) 感染性克隆
CN1833024A (zh) 含有衍生自基因型2a丙肝病毒(HCV)基因组的核酸的核酸构建体和具有转移入其中的这样的核酸构建体的细胞
CN1636015A (zh) Hcv e1e2疫苗组合物
CN1942585A (zh) 含人丙型肝炎病毒全长基因组的核酸构建物、核酸构建物转入其中的重组全长病毒基因组复制型细胞和生产丙型肝炎病毒颗粒的方法
CN1198933C (zh) 登革病毒的前m/m蛋白的表位、合成肽
CN1671851A (zh) 黄病毒疫苗输送系统
CN1553961A (zh) 包膜病毒的宿主范围突变及其作为疫苗基质的应用
CN1632124A (zh) 编码h5亚型禽流感病毒血凝素蛋白的基因及其应用
CN1898390A (zh) 用于在改良安卡拉痘苗病毒中进行表达的启动子
CN1160454C (zh) 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法
CN1570115A (zh) 优化的sars冠状病毒刺突蛋白基因
CN1531548A (zh) 编码可诱导抗病毒效应的蛋白质的嵌合链
HK1071691A (en) Chimeric flavivirus vectors
CN1882690A (zh) 从新hcv株衍生的核酸和基因以及使用所述基因的复制子－复制细胞

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1071691

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20041201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1071691

Country of ref document: HK